Fig. 4
HABP-HCQ prevents OVX-induced bone loss partially dependent on TRAF3. 10-week-old female TRAF3f/f and TRAF3f/f LysMcre (cKO) mice on a C57BL/6 background had sham or OVX surgery. From the 3rd d, OVX mice for each phenotype were randomly assigned to 5 treatment groups, which were given 5 doses per week of vehicle, HCQ (31.25 μmol/L/kg), HABP-HCQ (6.25 μmol/L/kg) or PTH [80 μg (19.4 nmol/L)/kg] or 1 weekly dose of zoledronic acid [0.15 mg (0.55 μmol/L) per mouse] for 5 weeks. a The spines were micro-CT scanned to quantify the bone structural parameters in L1 vertebrae. BP-H = HABP-HCQ, Zol = zoledronic acid. b TRAP-stained L4 vertebrae was used to quantify OC number and surface on eroded surfaces. black * = trabecular bone; red arrows = osteoclasts actively resorbing bone on the trabecular surface. Black arrows = giant osteoclasts without associated resorption lacunae. Blue arrows = osteoblasts on trabecular surface. c OB surfaces on trabeculae were quantified on H&E-stained sections from L4 vertebrae. 8-9 mice per group for all experiments. *P < 0.05, **P < 0.01, one-way ANOVA+Dunnett’s test
